Immuneering (IMRX) Cash from Operations (2020 - 2026)

Immuneering's Cash from Operations history runs 7 years deep, the most recent figure standing at 18433444.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 30.91% year-over-year to 18433444.0; the TTM figure through Mar 2026 stood at 49697401.0 (up 7.26% YoY), while the FY2025 annual figure was 45344595.0, up 17.55% from the prior year.
• Cash from Operations was 18433444.0 for Q1 2026 at Immuneering, down from 9840598.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 9446124.0 in Q2 2025 to a low of 18433444.0 in Q1 2026.
• Historically, Cash from Operations has averaged 12461618.18 across 5 years, with a median of 11977235.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 100.02% in 2022, then jumped 32.18% in 2025.
• A 5-year view of Cash from Operations shows it stood at 11748614.0 in 2022, then retreated by 0.23% to 11775201.0 in 2023, then declined by 23.23% to 14510513.0 in 2024, then soared by 32.18% to 9840598.0 in 2025, then tumbled by 87.32% to 18433444.0 in 2026.
• The last three Cash from Operations figures came in at 18433444.0 (Q1 2026), 9840598.0 (Q4 2025), and 11977235.0 (Q3 2025), per Business Quant data.